Key result
UCP2 G-866A variant linked to worse 5-year post-MI survival only in diabetic patients.
Why the study?
The impact of the UCP2 G-866A polymorphism on 5-year survival after myocardial infarction, particularly in diabetic patients, was unclear.
Does the UCP2 G-866A polymorphism affect 5-year survival in post-myocardial infarction patients with and without diabetes?
Population
901 post-myocardial infarction patients
Comparison
UCP2 G-866A AA/GA genotype vs GG genotype
Design
Cohort study
Follow-up
5 years
Authors
Loading...
May not yet guide post-MI risk stratification; leaves open UCP2 prognostic value in diabetes pending validation.
Cohort (n=901)
No
Does the UCP2 G-866A polymorphism affect 5-year survival in post-myocardial infarction patients with and without diabetes?
Absolute Event Rate: 15.6% vs 19.4%
p-value: p=0.541
The UCP2 -866 AA/GA genotype is associated with poorer 5-year survival and higher myeloperoxidase levels in diabetic patients following myocardial infarction.
Palmer et al. (2009) conducted a cohort in Post-myocardial infarction (n=901). UCP2 G-866A polymorphism (AA/GA genotypes) vs. GG genotype was evaluated on 5-year mortality (p=0.541). While UCP2 G-866A genotype was not associated with survival in the overall post-myocardial infarction cohort, diabetic patients with the AA or GA genotypes had significantly worse 5-year survival compared to those with the GG genotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: